Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) will take part in multiple investor conferences and fireside chats in early March 2026, including TD Cowen (March 3), UBS Biotech Summit (March 9), Leerink (March 10), Jefferies Biotech on the Beach (March 11), and Barclays (March 12).

Live webcasts of each presentation will be available under News and Events in the Investors section of the company website, with replays archived after the events.

Key Figures

TD Cowen conference time: March 3 at 9:10 a.m. ET Leerink conference time: March 10 at 11:20 a.m. ET Barclays conference time: March 12 at 9:30 a.m. ET +2 more

5 metrics

TD Cowen conference time March 3 at 9:10 a.m. ET TD Cowen 46th Annual Healthcare Conference fireside chat

Leerink conference time March 10 at 11:20 a.m. ET Leerink Partners Global Healthcare Conference fireside chat

Barclays conference time March 12 at 9:30 a.m. ET Barclays 28th Annual Global Healthcare Conference fireside chat

UBS summit date March 9 UBS Biotech Summit Miami participation

Jefferies summit date March 11 Jefferies Biotech on the Beach Summit participation

Market Reality Check

Price: $88.43 Vol: Volume 568,576 is about i...

normal vol

$88.43 Last Close

Volume Volume 568,576 is about in-line but below the 20-day average 781,719, suggesting no outsized trading interest ahead of these conferences. normal

Technical Shares at $88.43 are trading above the 200-day MA of $56.60, reflecting an established uptrend into the March conferences.

Peers on Argus

Sector data show 2 biotech peers in momentum screens moving down (median move -4...

2 Down

Sector data show 2 biotech peers in momentum screens moving down (median move -4.3%), indicating broader group volatility even as KYMR trades modestly higher (+1.18%) ahead of conferences.

Historical Context

5 past events · Latest: Feb 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Earnings timing update	Neutral	+0.1%	Announced date and webcast details for Q4 and full-year 2025 results.
Feb 04	Investor conferences	Neutral	+0.6%	Participation in February 2026 investor fireside chats and related webcasts.
Jan 29	Clinical trial progress	Positive	+3.9%	First patient dosed in BREADTH Phase 2b asthma trial of KT-621.
Jan 13	Strategy and cash update	Positive	+1.4%	Outlined 2026 objectives and reported an estimated $1.6B cash runway.
Jan 06	Major conference presentation	Neutral	+1.4%	Previewed J.P. Morgan Healthcare Conference presentation and webcast access.

Pattern Detected

Recent KYMR news, from conferences to clinical progress and strategy updates, has generally been followed by modestly positive price reactions, especially around clinical and cash runway disclosures.

Recent Company History

This announcement continues a steady cadence of investor outreach for Kymera Therapeutics. In January–February 2026, the company highlighted upcoming earnings timing, multiple investor conferences, and a key clinical milestone: first patient dosed in the BREADTH Phase 2b asthma trial of KT-621, with data timelines into 2027. A January strategy update paired this pipeline progress with an estimated $1.6 billion cash position supporting plans into 2029, framing the March conferences as part of an ongoing communication program.

Market Pulse Summary

This announcement expands Kymera’s investor-relations calendar with multiple March healthcare confer...

Analysis

This announcement expands Kymera’s investor-relations calendar with multiple March healthcare conferences, offering additional venues to discuss its oral immunology pipeline and 2026 objectives. Recent history includes a Phase 2b asthma trial start, a strategy update underpinned by an estimated $1.6 billion cash position, and steady conference participation. Investors may watch for any new clinical, partnership, or financial details emerging from these events, alongside ongoing insider trading disclosures and regulatory filings.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: 

• TD Cowen 46^th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;
• Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and
• Barclays 28^th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET.
  

In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively.

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events. 

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn. 

Investor Contact: 
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
857-285-5300 

Media Contact:
Matthew Henson
Vice President, Corporate Communications
mhenson@kymeratx.com
857-285-5300

FAQ

When and where will Kymera Therapeutics (KYMR) present at the TD Cowen conference?

Kymera will present at TD Cowen on March 3, 2026 at 9:10 a.m. ET. According to the company, the session is a fireside chat in Boston and will be available live via webcast under the Investors > News and Events section of its website.

How can investors watch Kymera Therapeutics (KYMR) presentations at the March 2026 conferences?

Investors can watch live webcasts on the company's investor website under News and Events. According to the company, each presentation will be webcast live and replays will be archived and available following the events for later viewing.

Which March 2026 investor events will Kymera Therapeutics (KYMR) attend in Miami?

Kymera will attend multiple Miami events on March 9–12, 2026 including UBS Biotech Summit, Leerink on March 10, Jefferies on March 11, and Barclays on March 12. According to the company, these include fireside chats and scheduled presentations with live webcasts.

Will Kymera Therapeutics (KYMR) provide replays of its March 2026 conference webcasts?

Yes. According to the company, replays of the live webcasts will be archived and available after each event. Investors should check the Investors > News and Events page on the company website for archived recordings and replay availability following the conferences.

What topics will Kymera Therapeutics (KYMR) cover during the March 2026 fireside chats?

The company will discuss its clinical-stage programs and corporate updates during the fireside chats. According to the company, the presentations are intended to highlight progress in its oral small molecule degrader programs for immunological diseases and provide investor updates.